Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc.    SLDB

SOLID BIOSCIENCES INC.

(SLDB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

SOLID BIOSCIENCES INC. : Other Events (form 8-K)

10/26/2020 | 08:06am EST

Item 8.01 Other Events

Sales Pursuant to Sales Agreement

On October 23, 2020, Solid Biosciences Inc. (the "Company") sold shares of its common stock pursuant to a sales agreement, dated March 13, 2019, between the Company and Jefferies LLC, that is expected to result in gross proceeds to the Company of $23.9 million upon final settlement (the "ATM Sales").

This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

Projected Cash Runway

The Company believes that its existing cash and cash equivalents as of September 30, 2020, together with the net proceeds from the previously announced issuance and sale of shares of its common stock to Ultragenyx Pharmaceutical Inc. on October 22, 2020 for an aggregate purchase price of approximately $40 million and the expected net proceeds from the ATM Sales, will enable it to fund its operating expenses into the second half of 2021. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently anticipates.

As previously disclosed, the Company expects to resume dosing in its IGNITE DMD Phase I/II clinical trial in the first quarter of 2021.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding the sufficiency of the Company's cash and cash equivalents to fund its operating expenses and the timing and ability of the Company to resume dosing in the IGNITE DMD clinical trial. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: risks associated with the Company's ability to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities, obtain and maintain the necessary approvals from investigational review boards at IGNITE DMD clinical trial sites and the IGNITE DMD data safety monitoring board, enroll patients in IGNITE DMD, continue to advance SGT-001 in clinical trials, replicate in clinical trials positive results found in preclinical studies and earlier stages of clinical development, advance the development of its product candidates under the timelines it anticipates in current and future clinical trials, successfully optimize and scale its manufacturing process, obtain, maintain or protect intellectual property rights related to its product candidates, compete successfully with other companies that are seeking to develop DMD/Duchenne treatments and gene therapies, manage expenses and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-001, achieve its other business objectives and continue as a going concern; general economic and market conditions; and other important risk factors set forth under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q and its other filings with the SEC. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SOLID BIOSCIENCES INC.
01/11SOLID BIOSCIENCES INC. : Regulation FD Disclosure (form 8-K)
AQ
01/08Sarepta's Mixed Results in Duchenne Muscular Dystrophy Trial Could be Good Ne..
MT
01/08SOLID BIOSCIENCES : Credit Suisse Upgrades Solid Biosciences to Neutral from Und..
MT
01/06Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
GL
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award, Prolongs Buy Trend
MT
2020INSIDER TRENDS : Solid Biosciences Insider Granted Stock Award, Extends Buy Tren..
MT
2020INSIDER TRENDS : Solid Biosciences Insider Receives Stock Award, Trend of Buys E..
MT
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award, Prolongs Buy Trend
MT
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award Retains Shares, Inte..
MT
2020MIDDAY REPORT : Wall Street Weaker Midday On Stimulus Woes
MT
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -87,8 M - -
Net cash 2020 60,6 M - -
P/E ratio 2020 -3,94x
Yield 2020 -
Capitalization 427 M 427 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 121
Free-Float 49,8%
Chart SOLID BIOSCIENCES INC.
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | SLDB | US83422E1055 | MarketScreener
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 6,70 $
Last Close Price 6,48 $
Spread / Highest target 92,9%
Spread / Average Target 3,40%
Spread / Lowest Target -69,1%
EPS Revisions
Managers and Directors
NameTitle
Ilan Ganot President, Chief Executive Officer & Director
Ian Frederick Smith Chairman
Jennifer Ziolkowski Chief Financial Officer & Treasurer
Carl Morris Chief Scientific Officer
Joel Schneider Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SOLID BIOSCIENCES INC.-14.51%427
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458